Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PKM | P14618 | 1/20 | 0.57 |
| ▸ | NPC1 | O15118 | 6/20 | 0.55 |
| ▸ | RAB9A | P51151 | 5/20 | 0.50 |
| ▸ | MAPT | P10636 | 4/20 | 0.50 |
| ▸ | LMNA | P02545 | 2/20 | 0.48 |
| ▸ | PDE10A | Q9Y233 | 2/20 | 0.43 |
| ▸ | MEN1 | O00255 | 4/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.43 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.43 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.43 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.43 |
| ▸ | RELA | Q04206 | 1/20 | 0.43 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.42 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.42 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.42 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.42 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.42 |
| ▸ | CASP3 | P42574 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8560189 | 0.84 | PKM (0.56) | PKMNPC1RAB9AMAPTLMNA | |
| SCHEMBL8560755 | 0.80 | PKM (0.57) | PKMNPC1RAB9AMAPTLMNA | |
| SCHEMBL9539135 | 0.76 | NPC1 (0.74) | PKMNPC1RAB9AMAPTLMNA | |
| SCHEMBL9304632 | 0.76 | NPC1 (0.56) | PKMNPC1RAB9AMAPTLMNA | |
| SCHEMBL4034758 | 0.75 | NPC1 (0.62) | PKMNPC1RAB9AMAPTLMNA | |
| SCHEMBL9685901 | 0.75 | PKM (0.57) | PKMNPC1RAB9AMAPTLMNA | |
| SCHEMBL5119326 | 0.74 | PDE10A (0.60) | PKMNPC1RAB9AMAPTLMNA | |
| SCHEMBL31631301 | 0.74 | NPC1 (0.74) | PKMNPC1RAB9AMAPTLMNA | |
| SCHEMBL1738419 | 0.74 | NPC1 (0.74) | PKMNPC1RAB9AMAPTLMNA | |
| SCHEMBL6837551 | 0.74 | NPC1 (0.70) | PKMNPC1RAB9AMAPTLMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7390811-B2 | Respiratory syncytial virus replication inhibitors | JANSSEN PHARMACEUTICA, N.V. (BE) | 2008-06-24 | — | — | US | disclosed |
| US-7361657-B2 | Respiratory syncytial virus replication inhibitors | JANSSEN PHARMACEUTICA, N.V. (BE) | 2008-04-22 | — | — | US | disclosed |
| US-7173054-B2 | Respiratory syncytial virus replication inhibitors | JANSSEN PHARMACEUTICA, N.V. (BE) | 2007-02-06 | — | — | US | disclosed |
| US-7173034-B2 | Respiratory syncytial virus replication inhibitors | JANSSEN PHARMACEUTICA, N.V. (BE) | 2007-02-06 | — | — | US | disclosed |
| US-20070021410-A1 | Respiratory syncytial virus replication inhibitors | JANSSEN PHARMACEUTICA, N.V. (BE) | 2007-01-25 | — | — | US | disclosed |
| US-20060154913-A1 | Respiratory syncytial virus replication inhibitors | JANSSEN PHARMACEUTICA, N.V (BE) (BE) | 2006-07-13 | — | — | US | disclosed |
| CN-1239496-C | Respiratory syncytial virus replication inhibitors | JANSSEN PHARMACEUTICA NV (BE) | 2006-02-01 | — | — | CN | disclosed |
| US-20050239771-A1 | Respiratory syncytial virus replication inhibitors | JANSSEN PHARMACEUTICA, N.V. | 2005-10-27 | — | — | US | disclosed |
| US-20050234047-A1 | Respiratory syncytial virus replication inhibitors | JANSSEN PHARMACEUTICA, N.V. | 2005-10-20 | — | — | US | disclosed |
| US-6924287-B1 | Respiratory syncytial virus replication inhibitors | JANSSEN PHARMACATICA, N.V. (BE) | 2005-08-02 | — | — | US | disclosed |
| CN-1358180-A | Respiratory syncytial virus replication inhibitors | JANSSEN PHARMACEUTICA NV (BE) | 2002-07-10 | — | — | CN | disclosed |
| EP-1196408-A1 | RESPIRATORY SYNCYTIAL VIRUS REPLICATION INHIBITORS | Janssen Pharmaceutica N.V. (BE) | 2002-04-17 | — | — | EP | disclosed |
| WO-2001000611-A1 | RESPIRATORY SYNCYTIAL VIRUS REPLICATION INHIBITORS | JANSSEN PHARMACEUTICA N.V. (BE) | 2001-01-04 | — | — | WO | disclosed |
| CN-1043640-C | Oxazolyl derivatives | JANSSEN PHARMACEUTICA NV (BE) | 1999-06-16 | — | — | CN | disclosed |
| EP-0539421-B1 | NOVEL OXAZOLYL DERIVATIVES | JANSSEN PHARMACEUTICA NV (BE) | 1998-09-23 | — | — | EP | disclosed |
| US-5278165-A | Oxazolyl imidazol[4,5-b]pyridin and pyrimidine compounds | JANSSEN PHARMACEUTICA N.V. (BE) | 1994-01-11 | — | — | US | disclosed |
| US-5217980-A | Antiallergens | JANSSEN PHARMACEUTICA N.V. (BE) | 1993-06-08 | — | — | US | disclosed |
| EP-0539421-A1 | NOVEL OXAZOLYL DERIVATIVES | JANSSEN PHARMACEUTICA N.V. (BE) | 1993-05-05 | — | — | EP | disclosed |
| WO-1992001687-A1 | NOVEL OXAZOLYL DERIVATIVES | JANSSEN PHARMACEUTICA N.V. (BE) | 1992-02-06 | — | — | WO | disclosed |
| CN-1058215-A | Novel oxazolyl derivatives | JANSSEN PHARMACEUTICA NV (BE) | 1992-01-29 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060154913-A1 | Respiratory syncytial virus replication inhibitors | CCNA1, CCNB3, CCNI | PKM 2841/4885NPC1 2728/4885RAB9A 1349/4885 |
| US-20050234047-A1 | Respiratory syncytial virus replication inhibitors | CCNA1, CCNB3, CCNI | PKM 2842/4885NPC1 2725/4885RAB9A 1342/4885 |
| US-20070021410-A1 | Respiratory syncytial virus replication inhibitors | CCNA1, CCNB3, CCNI | PKM 2841/4885NPC1 2728/4885RAB9A 1349/4885 |
| US-20050239771-A1 | Respiratory syncytial virus replication inhibitors | CCNB3, CCNA1, CDK2 | PKM 3060/4885NPC1 3084/4885RAB9A 1499/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.